OncoHost Receives New York State Laboratory Permit for Precision Oncology Test
The permit enables the company to offer its PROphetNSCLC test to physicians and patients across New York State, completing nationwide availability.
The permit enables the company to offer its PROphetNSCLC test to physicians and patients across New York State, completing nationwide availability.
Roche's VENTANA TROP2 RxDx Device, a computational companion diagnostic, has received FDA Breakthrough Device Designation.
Studies validated Biofidelity’s Aspyre Lung diagnostic tech, showcasing its ability to offer genomic profiling for actionable NSCLC variants.
Researchers developed a sensor that can detect low levels of isoprene in exhaled breath, potentially enabling early lung cancer diagnosis.
Read MoreNeoGenomics received conditional approval from the New York State Department of Health for its Neo Comprehensive Solid Tumor and NeoTYPE DNA & RNA Lung assays.
Read MoreBioAffinity Technologies’ noninvasive lung cancer test is available to Veterans and military personnel for early-stage lung cancer detection.
Read MoreA new microchip uses exosome analysis to detect lung cancer from a simple blood draw, enhancing speed and sensitivity in cancer diagnostics.
Read MoreThe MET Predict assists in identifying NSCLC tumors with MET exon 14 skipping or MET amplification directly from H&E whole slide images.
Read MoreSummary: DELFI Diagnostics appointed Thomas Russo as its new CFO to support the company’s...
Read MoreA new AI-driven digital pathology platform enables fully automated, rapid, and accurate analysis of lung cancer tissue.
Read MoreSeveral diagnostic associations announced the open comment period for the revised 2018 guideline on molecular testing for lung cancer.
Read MoreA new study from OncoHost reveals that its PROphetNSCLC test impacts oncologists’ first-line treatment decisions for metastatic NSCLC.
Read MoreResearchers have developed a potential exhaled-breath test for lung diseases by successfully collecting lung biomarkers from human breath.
Read MoreResearchers have developed an AI-powered liquid biopsy to identify lung cancer earlier through DNA fragment patterns in blood.
Read MoreDELFI’s blood-based Lung test has been clinically validated to enhance early detection of lung cancer, demonstrating high sensitivity.
Read MoreOncoHost will highlight the PROphet platform’s capability to predict benefits from therapies across various cancers.
Read MoreOSF HealthCare will use DELFI’s FirstLook Lung blood test to enhance lung cancer screening rates and early detection efforts.
Read MoreCAP developed recommendations for testing immunotherapy biomarkers, such as PD-L1 and TM), in patients with NSCLC.
Read More